Hiv Injection Clinical Trial
- All
- News
-
Revolutionary New Drug Offers 99.9% Protection Against HIV
The US FDA has approved lenacapavir, a groundbreaking long-acting HIV prevention drug that offers near-complete protection with just two injections per year. Despite its potential, concerns about high costs may limit its global impact.
-
Anti-HIV Injection Taken Twice A Year Shows 100% Efficacy: Study
The most common adverse effects were injection-site reactions experienced by close to 70 per cent of the participants in the Lenacapavir group.
-
Injection Twice A Year 100% Effective In HIV Treatment: Study
A large clinical trial in South Africa and Uganda has shown that a twice-yearly injection of a new pre-exposure prophylaxis drug gives young women total protection from HIV infection.
-
Revolutionary New Drug Offers 99.9% Protection Against HIV
The US FDA has approved lenacapavir, a groundbreaking long-acting HIV prevention drug that offers near-complete protection with just two injections per year. Despite its potential, concerns about high costs may limit its global impact.
-
Anti-HIV Injection Taken Twice A Year Shows 100% Efficacy: Study
The most common adverse effects were injection-site reactions experienced by close to 70 per cent of the participants in the Lenacapavir group.
-
Injection Twice A Year 100% Effective In HIV Treatment: Study
A large clinical trial in South Africa and Uganda has shown that a twice-yearly injection of a new pre-exposure prophylaxis drug gives young women total protection from HIV infection.
